The 36-month beta value for PLRX is also noteworthy at 1.41. There are mixed opinions on the stock, with 1 analysts rating it as a “buy”, 1 rating it as “overweight”, 10 rating it as “hold”, and 0 rating it as “sell”.
The public float for PLRX is 54.04M, and at present, short sellers hold a 6.23% of that float. The average trading volume of PLRX on July 03, 2025 was 1.15M shares.
PLRX stock’s latest price update
Pliant Therapeutics Inc (NASDAQ: PLRX) has seen a rise in its stock price by 3.75% in relation to its previous close of $1.2. However, the company has experienced a -4.23% decline in its stock price over the last five trading sessions. globenewswire.com reported 2025-06-27 that Bexotegrast development in IPF discontinued Clinical oncology program and early-stage programs continue Recent workforce and operational changes align with next steps SOUTH SAN FRANCISCO, Calif., June 27, 2025 (GLOBE NEWSWIRE) — Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that following the review of data from the recently terminated BEACON-IPF Phase 2b/3 clinical trial, the Company has discontinued development of bexotegrast in idiopathic pulmonary fibrosis (IPF).
PLRX’s Market Performance
Pliant Therapeutics Inc (PLRX) has seen a -4.23% fall in stock performance for the week, with a -22.19% decline in the past month and a -11.70% plunge in the past quarter. The volatility ratio for the week is 10.18%, and the volatility levels for the past 30 days are at 8.69% for PLRX. The simple moving average for the past 20 days is -8.47% for PLRX’s stock, with a -82.93% simple moving average for the past 200 days.
PLRX Trading at -11.87% from the 50-Day Moving Average
After a stumble in the market that brought PLRX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -92.27% of loss for the given period.
Volatility was left at 8.69%, however, over the last 30 days, the volatility rate increased by 10.18%, as shares sank -27.71% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -20.00% lower at present.
During the last 5 trading sessions, PLRX fell by -7.69%, which changed the moving average for the period of 200-days by -90.00% in comparison to the 20-day moving average, which settled at $1.3580. In addition, Pliant Therapeutics Inc saw -88.54% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at PLRX starting from Coulie Bernard, who sold 52,419 shares at the price of $11.20 back on Jan 17 ’25. After this action, Coulie Bernard now owns 430,517 shares of Pliant Therapeutics Inc, valued at $587,150 using the latest closing price.
Cummings Keith Lamont, the Chief Financial Officer of Pliant Therapeutics Inc, sale 20,148 shares at $11.20 during a trade that took place back on Jan 17 ’25, which means that Cummings Keith Lamont is holding 262,608 shares at $225,680 based on the most recent closing price.
Stock Fundamentals for PLRX
The total capital return value is set at -0.74%. Equity return is now at value -63.22%, with -50.67% for asset returns.
Based on Pliant Therapeutics Inc (PLRX), the company’s capital structure generated 0.19 points at debt to capital in total, while cash flow to debt ratio is standing at -2.89. The debt to equity ratio resting at 0.23. The interest coverage ratio of the stock is -69.54.
Currently, EBITDA for the company is -228.37 million with net debt to EBITDA at 0.15. The liquidity ratio also appears to be rather interesting for investors as it stands at 11.03.
Conclusion
In summary, Pliant Therapeutics Inc (PLRX) has had a bad performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.